Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Recruiting
This is an international, multicenter study with two components: Registry * A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection * Enrollment is open to all genes on the RD Rare Gene List Natural History Study * A prospective, standardized, longitudinal Natural History Study * Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives 1. Genotype Character... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
08/01/2025
Locations: University of Arkansas, Jones Eye Institute, Little Rock, Arkansas +36 locations
Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Register for Updates
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223
Recruiting
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +72 locations
Conditions: Metastatic Colorectal Cancer
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Associated Retina Consultans, Gilbert, Arizona +154 locations
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +251 locations
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Register for Updates
Healthy Ageing: a Feasibility Study to Evaluate Digitally-enabled Ways to Support Healthy Ageing
NCT07112352
Recruiting
The goal of this clinical trial is to learn if it is feasibility to conduct a trial of two digitally-enabled interventions that support older adults to adopt healthy behaviours. It will also learn about the safety of this digital intervention. The main questions it aims to answer are * How acceptable and feasible are the trial, intervention and control groups in assessing outcomes * What is the estimated effect of the interventions? Researchers will compare Smart devices with a bespoke 'Healthy... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/01/2025
Locations: Helix Centre, Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, London, Not set
Conditions: Frailty, Older Adults (65 Years and Older), Digital Health Intervention, Feasibility Studies
Register for Updates
Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656
Recruiting
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/01/2025
Locations: #1016, Mayo Clinic, Phoenix, Arizona +21 locations
Conditions: Advanced Solid Tumor
Register for Updates
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564
Recruiting
This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
Gender:
MALE
Ages:
3 years and below
Trial Updated:
08/01/2025
Locations: Chr de La Citadelle, Liege, Not set +6 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +73 locations
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Register for Updates
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
07/31/2025
Locations: Research Site, Huntsville, Alabama +390 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976
Recruiting
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Local Institution - 0046, Mobile, Alabama +216 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Site US10052, Anchorage, Alaska +235 locations
Conditions: Prostate Cancer
Register for Updates
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2025
Locations: Banner Desert Medical Center, Mesa, Arizona +75 locations
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Register for Updates